Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease
Donanemab, an investigational antibody that targets a modified form of beta amyloid, showed significant slowing of decline in cognition and daily function.
Lilly’s Donanemab Slows Clinical Decline of Alzheimer’s Disease Read More »